Investing.com - TransAct (NASDAQ: TACT) reported first quarter EPS of $-0.44, $0.34 worse than the analyst estimate of $-0.10. Revenue for the quarter came in at $22.3M versus the consensus estimate of $14.78M.
Guidance
TransAct sees FY 2023 revenue of $70.00M-$72.00M versus the analyst consensus of $62.43M.
TransAct's stock price closed at $5.84. It is down -20.11% in the last 3 months and up 2.64% in the last 12 months.
TransAct saw positive EPS revisions and negative EPS revisions in the last 90 days. See TransAct's stock price’s past reactions to earnings here.
According to InvestingPro, TransAct's Financial Health score is "fair performance".
Check out TransAct's recent earnings performance, and TransAct's financials here.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar